Results 11 to 20 of about 1,814 (132)

Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study

Indian Journal of Ophthalmology, 2023
Purpose: To report the incidence, clinical features, potential risk factors, and outcomes of intraocular inflammation (IOI) following brolucizumab in Indian eyes. Methods: All consecutive patients diagnosed with brolucizumab-induced IOI from 10 centers
Debdulal Chakraborty, Soumen Mondal, Sabyasachi Sengupta, Zahir Abbas, Khushboo Chandra, Subhendu Boral, Aniruddha Maiti, Sangeeta Roy, Angshuman Mukherjee, Arnab Das, Somnath Chakraborty, Pinaki Nag   +11 more
doaj   +1 more source

The effect of intravitreal brolucizumab on choroidal thickness in patients with neovascular age-related macular degeneration

Scientific Reports, 2022
In this study we evaluated the effect of intravitreal brolucizumab injections on choroidal thickness in patients with neovascular age-related macular degeneration (nAMD) who previously showed an incomplete response to anti-vascular endothelial growth ...
Ki Woong Bae, Dong Ik Kim, Daniel Duck-Jin Hwang   +2 more
doaj   +1 more source

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy

BMC Health Services Research, 2022
Background Age-related macular degeneration (AMD) is a common and chronic eye condition characterized by the presence of progressive degenerative abnormalities in the central retina (macula).
Nicola Ferrante, Daniela Ritrovato, Rossella Bitonti, Gianluca Furneri   +3 more
doaj   +1 more source

Angiographic findings before and after the onset of brolucizumab-associated retinal vascular occlusion and intraocular inflammation

American Journal of Ophthalmology Case Reports, 2022
Purpose: To describe angiographic features of a case of delayed-onset retinal vascular occlusion and intraocular inflammation (IOI) following brolucizumab intravitreal injection (IVI).
Sentaro Kusuhara, Kyung Woo Kim, Akiko Miki, Makoto Nakamura   +3 more
doaj   +1 more source

Response to brolucizumab treatment for refractory serous pigment epithelial detachment secondary to polypoidal choroidal vasculopathy

BMC Ophthalmology, 2022
Purpose To report the efficacy and safety of brolucizumab in the treatment of refractory serous pigment epithelial detachment (PED) secondary to polypoidal choroidal vasculopathy (PCV). Methods Twenty-six eyes of 26 patients were included.
Seung Wan Nam, Zeeyoon Byun, Don-Il Ham, Mingui Kong   +3 more
doaj   +1 more source

Brolucizumab in Pretreated Neovascular Age-Related Macular Degeneration: Case Series, Systematic Review, and Meta-Analysis

Life, 2023
Background: Recalcitrant neovascular age-related macular degeneration (rnAMD) despite intensive intravitreal anti-neovascular endothelial growth factor (VEGF) treatment, can be handled by switching to another anti-VEGF agent. This first systematic review
Christof Hänsli, Christin Schild, Isabel Pfister, Justus G. Garweg   +3 more
doaj   +1 more source

Swept-source optical coherence tomography angiography of retinal occlusive vasculitis following brolucizumab administration: a case report

BMC Ophthalmology, 2022
Background We present a case of retinal occlusive vasculitis following brolucizumab administration and the first report of optical coherence tomography angiography (OCTA) findings after treatment.
Eun Kyoung Lee, Baek-Lok Oh, Chang Ki Yoon, Un Chul Park   +3 more
doaj   +1 more source

Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series

American Journal of Ophthalmology Case Reports, 2021
Purpose: To report the efficacy of intravitreal injection (IVI) of brolucizumab for recalcitrant diabetic macular edema (DME) in a real-world setting. Observations: This was a single-center, prospective uncontrolled non-randomized case series. Three eyes
Debdulal Chakraborty, Jay U. Sheth, Subhendu Boral, Tushar K. Sinha   +3 more
doaj   +1 more source

Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization

Scientific Reports, 2023
We previously reported one-year results of a treat-and-extend (TAE) regimen with intravitreal brolucizumab for 68 eyes with treatment-naïve neovascular age-related macular degeneration (nAMD) associated with type 1 macular neovascularization (MNV).
Hidetaka Matsumoto, Junki Hoshino, Kosuke Nakamura, Hideo Akiyama   +3 more
doaj   +1 more source

Intravitreal brolucizumab as treatment of early onset radiation retinopathy secondary to plaque brachytherapy for choroidal melanoma

American Journal of Ophthalmology Case Reports, 2022
Purpose: To describe the efficacy and safety of brolucizumab (Beovu®, Novartis Pharmaceuticals) in a case of cystoid macular edema associated with radiation retinopathy as a result of iodine-125 plaque brachytherapy (PBT) for choroidal melanoma ...
Natacha C. Villegas, Kapil Mishra, Nathan Steinle, Wu Liu, Beth Beadle, Prithvi Mruthyunjaya   +5 more
doaj   +1 more source